Kezar changes CEOs, lays off 41% of staff and halts pre­clin­i­cal R&D to ex­tend cash run­way

Kezar Life Sci­ences, a 2015 spin­out from Am­gen, is lay­ing off 41% of its work­force and paus­ing all pre­clin­i­cal R&D in a bid to ex­tend its cash run­way in­to late 2026 and move se­lect clin­i­cal pro­grams for­ward, the biotech said Tues­day.

There are al­so sev­er­al ex­ec­u­tive shake­ups: Kezar said co-founder John Fowler will re­sign as CEO on Nov. 7 and for­mer pres­i­dent and CSO Christo­pher Kirk will take over as CEO. CMO Noreen Henig is re­sign­ing on Oct. 6 and Zung To, the se­nior VP of clin­i­cal de­vel­op­ment op­er­a­tions, will take over tri­al ex­e­cu­tion and de­vel­op­ment op­er­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER